Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Spyre Therapeutics Inc.

    NASDAQ: SYRE · Real-Time Price · USD
    16.78
    -0.40 (-2.33%)
    At close: Jun 17, 2025, 10:36 AM

    Spyre Therapeutics Statistics

    Share Statistics

    Spyre Therapeutics has 60.35M shares outstanding. The number of shares has increased by 18.66% in one year.

    Shares Outstanding

    n/a
    		 60.35M

    Shares Change (YoY)

    n/a
    		 18.66%

    Shares Change (QoQ)

    n/a
    		 2.64%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 51.32M

    Failed to Deliver (FTD) Shares

    n/a
    		 87

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 12.09M, so 20.03% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 12.09M

    Short % of Shares Out

    n/a
    		 20.03%

    Short % of Float

    n/a
    		 25.72%

    Short Ratio (days to cover)

    n/a
    		 33.21

    Valuation Ratios

    The PE ratio is -41.9 and the forward PE ratio is -5.25. Spyre Therapeutics's PEG ratio is 0.42.

    PE Ratio

    n/a
    		 -41.9

    Forward PE

    n/a
    		 -5.25

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 16.83

    P/FCF Ratio

    n/a
    		 -55.37

    PEG Ratio

    n/a
    		 0.42
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Spyre Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 11.26, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 11.26

    Quick Ratio

    n/a
    		 11.26

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-2,849,561.64

    Employee Count

    n/a
    		 73

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 51K

    Effective Tax Rate

    n/a
    		 -0.02%

    Stock Price Statistics

    The stock price has increased by -32.25% in the last 52 weeks. The beta is 2.73, so Spyre Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.73

    52-Week Price Change

    n/a
    		 -32.25%

    50-Day Moving Average

    n/a
    		 14.71

    200-Day Moving Average

    n/a
    		 22.82

    Relative Strength Index (RSI)

    n/a
    		 59.15

    Average Volume (20 Days)

    n/a
    		 625,274

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -208.57M

    Net Income

    n/a
    		 -208.02M

    EBITDA

    n/a
    		 -207.97M

    EBIT

    n/a
    		 -207.97M

    Earnings Per Share (EPS)

    n/a
    		 -0.56
    Full Income Statement

    Balance Sheet

    The company has 89.42M in cash and 0 in debt, giving a net cash position of 89.42M.

    Cash & Cash Equivalents

    n/a
    		 89.42M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -972.43M

    Total Assets

    n/a
    		 569.78M

    Working Capital

    n/a
    		 499.09M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -157.41M and capital expenditures 0, giving a free cash flow of -157.41M.

    Operating Cash Flow

    n/a
    		 -157.41M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -157.41M

    FCF Per Share

    n/a
    		 -0.42
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    SYRE does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for SYRE is $55, which is 219.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $55

    Price Target Difference

    n/a
    		 219.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Sep 8, 2023. It was a backward split with a ratio of 1:25.

    Last Split Date

    n/a
    		 Sep 8, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:25

    Scores

    Altman Z-Score

    n/a
    		 3.77

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist